The Latest Advances in the Management of Atopic Dermatitis and the Role of JAK Inhibitors: Best Practices for the Pharmacist

Program Description

The Janus kinase (JAK) pathway has emerged as a critical target to control inflammation in atopic dermatitis (AD). Several JAK inhibitors have recently been approved and many others are still under investigation for the management of AD. This podcast will specifically focus on clinical safety and efficacy data supporting the use of new and emerging JAK inhibitors in the management of AD. Practical counseling points for pharmacists to provide individualized care and proper selection of therapy to patients with AD who are initiating therapy with JAK inhibitors will also be discussed.

Target audience: Specialty pharmacists
Type of activity: Knowledge
Release date: June 30, 2022
Expiration date: June 30, 2023
Time to complete activity: 0.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Understand the impact of Janus kinase inhibitors for the management of atopic dermatitis (AD)
• Examine key safety and efficacy data on new and emerging Janus kinase inhibitors utilized for the treatment of AD and select appropriate treatments
• Identify the role of the pharmacist in individualizing treatment for patients with AD through patient counseling and education

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-321-H01-P. The activity is available for CE credit through June 30, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, listen to the podcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Svetlana Gerzenshtein, PharmD, BCPS, CSP, has no relevant financial relationships with commercial interests to disclose.

Faculty

Sarah Lant, PharmD, has the following relevant financial relationship with a commercial interest to disclose:
Other (faculty speaker training): Lilly

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms